FULC · Fulcrum Therapeutics, Inc.
$3.84
+0.01 (+0.26%)
At close · Aug 24
Market Cap
$292.22M
Shares
76.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2025
Net Income
-$74.88M
-670%
FY2025
Operating Margin
-27.37%
+3917.9pp
FY2024
Diluted EPS
-$1.18
-637.5%
FY2025
Operating Cash Flow
-$60.07M
-2608.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $80M | $2.81M | $6.34M | $19.16M | $8.82M | — | — | |
| $56.24M | $56.1M | $63.39M | $71.8M | $76.78M | $69.7M | $59.04M | $71.07M | $25.18M | |
| $30.4M | $28.67M | $36.45M | $41.67M | $41.69M | $30.52M | $21.39M | $13.15M | $8.31M | |
| — | $400K | $1.7M | — | $400K | — | — | — | — | |
| $96.05M | $84.77M | $101.9M | $113.47M | $118.9M | $100.22M | $80.43M | $84.22M | $33.5M | |
| -$96.05M | -$84.77M | -$21.9M | -$110.66M | -$112.56M | -$81.05M | -$71.61M | -$84.22M | -$33.5M | |
| — | — | -27.37% | -3945.24% | -1774.85% | -422.97% | -811.64% | — | — | |
| — | $0 | $0 | — | — | — | — | — | — | |
| -$85M | -$74.88M | -$9.73M | -$97.34M | -$109.87M | -$80.85M | -$70.82M | -$82.68M | -$32.59M | |
| — | — | -12.16% | -3470.05% | -1732.43% | -421.89% | -802.66% | — | — | |
| — | — | — | — | — | — | -$70.82M | -$89.81M | -$39.15M | |
| -$85.65M | -$74.84M | -$9.46M | -$96.67M | -$110.27M | -$81.24M | -$70.82M | -$82.68M | — | |
| USD/shares | — | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | -$2.79 | — | — |
| USD/shares | — | -$1.18 | -$0.16 | -$1.59 | -$2.44 | -$2.29 | -$2.79 | — | — |
| shares | — | 63.36K | 61.98K | 61.31K | 44.99K | 35.36K | 25.35K | 11.05K | 1257 |
| shares | — | 63.36K | 61.98K | 61.31K | 44.99K | 35.36K | 25.35K | 11.05K | 1257 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.27×
EV/EBIT
—
Peer median 9.64×
P/E (TTM)
—
Peer median 11.22×
Peer medians compare against the 313 similar-size Biotechnology companies (of 533 listed).
Key facts
CIK
1680581
CUSIP
359616109
13F (30d)
154 filings
140 filers
Visit website
Investor relations